News | April 25, 2023
Boehringer Ingelheim inaugurates largest European development centre for biotechnology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Several late-stage pipeline products have the potential to address some of these unmet needs
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Bourgoin early development hub broadens offerings for oral solid dose formulations
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Subscribe To Our Newsletter & Stay Updated
